Literature DB >> 9839277

Angiotensin II, nitric oxide, and end-organ damage in hypertension.

A Bataineh1, L Raij.   

Abstract

The adaptive changes that accompany hypertension and involve the kidney, heart, and vessels, namely, muscle hypertrophy/hyperplasia, endothelial dysfunction and extracellular matrix increase can, in fact, be maladaptive and eventually lead to end-organ disease, such as renal failure, heart failure, and coronary disease. However, these changes vary markedly between individuals with similar levels of hypertension. Nitric oxide (NO), an endogenous vasodilator and inhibitor of vascular smooth muscle and mesangial cell growth, is synthesized in the endothelium by a constitutive NO synthase (NOS). NO antagonizes the effects of angiotensin II on vascular tone and growth and also down-regulates the synthesis of angiotensin converting enzyme (ACE) and angiotensin II type 1 (AT-1) receptors. In hypertension, the physiologic response to the increased shear stress and cyclic strain is to upregulate NOS activity in endothelial cells. Upregulation of vascular NOS activity is a homeostatic adaptation to the increased hemodynamic workload that may help in preventing end-organ damage. Indeed, hypertension-prone salt-sensitive rats manifest a decrease (instead of an increase) in vascular NOS activity when hypertensive; these rats develop severe vascular hypertrophy, left ventricular hypertrophy, and renal injury. Studies in hypertensive humans suggest that, independent of the effects of salt on blood pressure, salt sensitivity may be a marker for susceptibility to the development of endothelial dysfunction as well as cardiovascular and renal injury. We hypothesize that in hypertension, recognition of markers of cardiovascular susceptibility to injury and the understanding of the pathophysiological mechanisms involved may open new opportunities for therapeutic intervention. In this context, only those antihypertensive agents that lower blood pressure and concomitantly restore the homeostatic balance of vasoactive agents such as angiotensin II and NO within the vessel wall would be effective in preventing or arresting end-organ disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9839277     DOI: 10.1046/j.1523-1755.1998.06806.x

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  6 in total

1.  The antihypertensive effect of cysteine.

Authors:  Sudesh Vasdev; Pawan Singal; Vicki Gill
Journal:  Int J Angiol       Date:  2009

2.  The cardiorenal syndrome: making the connection.

Authors:  Gautham Viswanathan; Scott Gilbert
Journal:  Int J Nephrol       Date:  2010-10-04

3.  TRPV4 activation mediates flow-induced nitric oxide production in the rat thick ascending limb.

Authors:  Pablo D Cabral; Jeffrey L Garvin
Journal:  Am J Physiol Renal Physiol       Date:  2014-06-25

4.  Endothelin-1, big endothelin-1, and nitric oxide in patients with chronic renal disease and hypertension.

Authors:  Ivanka Mikulić; József Petrik; Kresimir Galesić; Zeljko Romić; Ivana Cepelak; Monika Zeljko-Tomić
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

5.  Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension.

Authors:  Tang-Dong Liao; Xiao-Ping Yang; Yun-He Liu; Edward G Shesely; Maria A Cavasin; William A Kuziel; Patrick J Pagano; Oscar A Carretero
Journal:  Hypertension       Date:  2008-06-09       Impact factor: 10.190

Review 6.  Hypertension: what's sex got to do with it?

Authors:  Margaret A Zimmerman; Jennifer C Sullivan
Journal:  Physiology (Bethesda)       Date:  2013-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.